Homepage Top Section2

In this connection, Novaremed has filed an investigational new drug (IND) application to the FDA. The clinical-stage Swiss biopharma company revealed to have got initial feedback from the

The Canadian biopharma company expects to immediately begin recruitment for the mid-stage trial of favipiravir with an aim to enroll nearly 760 subjects from both residents and staff

The company has reported positive interim clinical data of mRNA-1273 from the phase 1 study by the National Institute of Allergy and Infectious Diseases (NIAID), part of the

Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) that includes an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent monomethyl auristatin E (MMAE)

As per terms of the deal, Catalent will involve in the development of a powder-in-capsule formulation for Ennaid’s ENU200 programme. Ennaid’s ENU200 is a patent-pending and repurposed oral

In the late-stage trial called IKEMA, Sarclisa, when added to carfilzomib and dexamethasone, met the primary endpoint by delivering significantly prolonged progression-free survival compared to standard of care

In this regard, the Texas-based Acer Therapeutics has signed a research collaboration agreement with NCATS, which is one of the National Institutes of Health (NIH) in the US.

According to jCyte, treatment with jCell is a minimally-invasive intravitreal injection, which can be carried out in an ophthalmologist’s office with topical anesthetic. The entire procedure is said

Enhertu, a HER2-directed antibody drug conjugate (ADC), is being studied under a comprehensive development programme to assess the efficacy and safety of the monotherapy across multiple HER2-driven cancers